This prospective trial, in which 100 patients with malignant neoplasm participated, was based on the background that FAP is overexpressed in CAFs, which is closely related to tumor growth, invasion, metastasis, immunosuppression, and prognosis, while the expression level of FAP in normal tissues and organs is very low. The gene discussed is FAP; the disease is cancer.